Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 933

1.

Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies.

Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, Croze E, Aftab BT, Giovannoni G, Joshi MJ.

Trends Mol Med. 2019 Dec 17. pii: S1471-4914(19)30294-1. doi: 10.1016/j.molmed.2019.11.003. [Epub ahead of print] Review.

2.

Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders.

Ringelstein M, Harmel J, Zimmermann H, Brandt AU, Paul F, Haarmann A, Buttmann M, Hümmert MW, Trebst C, Schroeder C, Ayzenberg I, Kleiter I, Hellwig K, Havla J, Kümpfel T, Jarius S, Wildemann B, Rommer P, Weber MS, Pellkofer H, Röpke L, Geis C, Retzlaff N, Zettl U, Deppe M, Klotz L, Young K, Stellmann JP, Kaste M, Kermer P, Marouf W, Lauda F, Tumani H, Graf J, Klistorner A, Hartung HP, Aktas O, Albrecht P; Neuromyelitis Optica Study Group (NEMOS).

Neurology. 2019 Dec 3. pii: 10.1212/WNL.0000000000008684. doi: 10.1212/WNL.0000000000008684. [Epub ahead of print]

PMID:
31796527
3.

Meningitis gone viral: description of the echovirus wave 2013 in Germany.

Graf J, Hartmann CJ, Lehmann HC, Otto C, Adams O, Karenfort M, Schneider C, Ruprecht K, Bosse HM, Diedrich S, Böttcher S, Schnitzler A, Hartung HP, Aktas O, Albrecht P.

BMC Infect Dis. 2019 Nov 29;19(1):1010. doi: 10.1186/s12879-019-4635-6.

4.

Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis.

Cruz-Herranz A, Dietrich M, Hilla AM, Yiu HH, Levin MH, Hecker C, Issberner A, Hallenberger A, Cordano C, Lehmann-Horn K, Balk LJ, Aktas O, Ingwersen J, von Gall C, Hartung HP, Zamvil SS, Fischer D, Albrecht P, Green AJ.

J Neuroinflammation. 2019 Nov 4;16(1):203. doi: 10.1186/s12974-019-1583-4.

5.

Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.

Albrecht P, Jansen A, Lee JI, Aktas O, Bigalke H, Hartung HP, Hefter H.

Neurology. 2019 Oct 22;93(17):768-769. doi: 10.1212/WNL.0000000000008381. No abstract available.

PMID:
31636233
6.

Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.

Albrecht P, Jansen A, Lee JI, Ringelstein M, Aktas O, Hartung HP, Bigalke H, Hefter H.

Neurology. 2019 Oct 22;93(17):767-768. doi: 10.1212/WNL.0000000000008378. No abstract available.

PMID:
31636231
7.

Heterogeneous fate choice of genetically modulated adult neural stem cells in gray and white matter of the central nervous system.

Beyer F, Jadasz J, Samper Agrelo I, Schira-Heinen J, Groh J, Manousi A, Bütermann C, Estrada V, Reiche L, Cantone M, Vera J, Viganò F, Dimou L, Müller HW, Hartung HP, Küry P.

Glia. 2020 Feb;68(2):393-406. doi: 10.1002/glia.23724. Epub 2019 Oct 21.

PMID:
31633850
8.

Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.

Verboon C, van den Berg B, Cornblath DR, Venema E, Gorson KC, Lunn MP, Lingsma H, Van den Bergh P, Harbo T, Bateman K, Pereon Y, Sindrup SH, Kusunoki S, Miller J, Islam Z, Hartung HP, Chavada G, Jacobs BC, Hughes RAC, van Doorn PA; IGOS Consortium.

J Neurol Neurosurg Psychiatry. 2020 Feb;91(2):113-121. doi: 10.1136/jnnp-2019-321496. Epub 2019 Oct 5.

PMID:
31586949
9.

Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.

Haas J, Jeffery D, Silva D, Meier DP, Meinert R, Cohen J, Hartung HP.

Mult Scler Relat Disord. 2019 Nov;36:101335. doi: 10.1016/j.msard.2019.07.011. Epub 2019 Jul 20.

PMID:
31557679
10.

The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis.

Penner IK, Hartung HP.

Brain. 2019 Sep 1;142(9):2552-2555. doi: 10.1093/brain/awz234. No abstract available.

PMID:
31497861
11.

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators.

Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5.

PMID:
31495497
12.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators.

Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.

PMID:
31492652
13.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators.

Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3.

PMID:
31492651
14.

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.

Barkhof F, Kappos L, Wolinsky JS, Li DKB, Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL.

Neurology. 2019 Nov 5;93(19):e1778-e1786. doi: 10.1212/WNL.0000000000008189. Epub 2019 Sep 4.

PMID:
31484710
15.

Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.

Hartung HP, Mallick R, Bril V, Lewis RA, Sobue G, Lawo JP, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, van Schaik IN; PATH study group.

Eur J Neurol. 2020 Jan;27(1):196-203. doi: 10.1111/ene.14056. Epub 2019 Sep 23.

PMID:
31400231
16.

Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data.

Sinnecker T, Hadisurya J, Schneider-Hohendorf T, Schwab N, Wrede K, Gembruch O, Gold R, Hellwig K, Pilgram-Pastor S, Adams O, Albrecht P, Hartung HP, Aktas O, Kraemer M.

BMC Neurol. 2019 Aug 9;19(1):190. doi: 10.1186/s12883-019-1407-2.

17.

Big data in MS-What can we learn from large international observational studies such as MSBase?

Warnke C, Hartung HP.

Mult Scler. 2020 Jan;26(1):4-5. doi: 10.1177/1352458519868982. Epub 2019 Aug 9. No abstract available.

PMID:
31397200
18.

The Molecular Basis for Remyelination Failure in Multiple Sclerosis.

Gruchot J, Weyers V, Göttle P, Förster M, Hartung HP, Küry P, Kremer D.

Cells. 2019 Aug 3;8(8). pii: E825. doi: 10.3390/cells8080825. Review.

19.

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 3;6(5):e590. doi: 10.1212/NXI.0000000000000590. eCollection 2019 Sep.

20.

No Alteration of Optical Coherence Tomography and Multifocal Visual Evoked Potentials in Eyes With Symptomatic Carotid Artery Disease.

Lee JI, Gemerzki L, Boerker L, Guthoff R, Aktas O, Gliem M, Jander S, Hartung HP, Albrecht P.

Front Neurol. 2019 Jul 10;10:741. doi: 10.3389/fneur.2019.00741. eCollection 2019.

21.

Drug Treatment of Clinically Isolated Syndrome.

Förster M, Graf J, Mares J, Aktas O, Hartung HP, Kremer D.

CNS Drugs. 2019 Jul;33(7):659-676. doi: 10.1007/s40263-019-00647-x. Review.

PMID:
31290079
22.

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators.

Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5.

PMID:
31285147
23.

Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases.

Graf J, Ingwersen J, Lepka K, Albrecht P, Hartung HP, Ringelstein M, Aktas O.

Acta Neurol Scand. 2019 Oct;140(4):290-295. doi: 10.1111/ane.13144. Epub 2019 Jul 23.

PMID:
31269227
24.

pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis.

Kremer D, Gruchot J, Weyers V, Oldemeier L, Göttle P, Healy L, Ho Jang J, Kang T Xu Y, Volsko C, Dutta R, Trapp BD, Perron H, Hartung HP, Küry P.

Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15216-15225. doi: 10.1073/pnas.1901283116. Epub 2019 Jun 18.

25.

Clinical trials in multiple sclerosis: potential future trial designs.

Manouchehri N, Zhang Y, Salter A, Hussain RZ, Hartung HP, Hemmer B, Linker R, Segal BM, Cutter G, Stüve O.

Ther Adv Neurol Disord. 2019 May 13;12:1756286419847095. doi: 10.1177/1756286419847095. eCollection 2019. Review.

26.

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.

Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, Markowitz GS, Margolin DH, Rodriguez CE, Baker DP, Coles AJ.

Mult Scler. 2019 Aug;25(9):1273-1288. doi: 10.1177/1352458519841829. Epub 2019 Apr 15.

27.

Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis.

Schweitzer F, Laurent S, Fink GR, Barnett MH, Reddel S, Hartung HP, Warnke C.

Curr Opin Neurol. 2019 Jun;32(3):305-312. doi: 10.1097/WCO.0000000000000701.

PMID:
30985373
28.

Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm.

Cree BAC, Mares J, Hartung HP.

Curr Opin Neurol. 2019 Jun;32(3):365-377. doi: 10.1097/WCO.0000000000000700.

PMID:
30985372
29.

Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change.

Hartung HP, Graf J, Aktas O, Mares J, Barnett MH.

Curr Opin Neurol. 2019 Jun;32(3):327-337. doi: 10.1097/WCO.0000000000000699.

PMID:
30985371
30.

Challenging a concept: Pulsed treatment regimen-No risk of PML?

Warnke C, Hartung HP.

Mult Scler. 2019 Jul;25(8):1076-1078. doi: 10.1177/1352458519843232. Epub 2019 Apr 9. No abstract available.

PMID:
30964427
31.

Endovascular Thrombectomy as a Means to Improve Survival in Acute Ischemic Stroke: A Meta-analysis.

Lin Y, Schulze V, Brockmeyer M, Parco C, Karathanos A, Heinen Y, Gliem M, Hartung HP, Antoch G, Jander S, Turowski B, Perings S, Kelm M, Wolff G.

JAMA Neurol. 2019 Jul 1;76(7):850-854. doi: 10.1001/jamaneurol.2019.0525.

PMID:
30958530
32.

Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells.

Prozorovski T, Ingwersen J, Lukas D, Göttle P, Koop B, Graf J, Schneider R, Franke K, Schumacher S, Britsch S, Hartung HP, Küry P, Berndt C, Aktas O.

Neurosci Lett. 2019 Jun 21;704:116-125. doi: 10.1016/j.neulet.2019.04.007. Epub 2019 Apr 4.

PMID:
30953735
33.

Prominent T-Cell Responses against the Acetylcholine Receptor ε Subunit in Myasthenia Gravis.

Neuhaus O, Wiesmüller KH, Hartung HP, Wiendl H.

Neurol Res Int. 2019 Mar 3;2019:1969068. doi: 10.1155/2019/1969068. eCollection 2019.

34.

CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography.

Aktas O, Hartung HP.

Ann Neurol. 2019 May;85(5):615-617. doi: 10.1002/ana.25471. Epub 2019 Apr 10. No abstract available.

PMID:
30900764
35.

An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis.

Amedonu E, Brenker C, Barman S, Schreiber JA, Becker S, Peischard S, Strutz-Seebohm N, Strippel C, Dik A, Hartung HP, Budde T, Wiendl H, Strünker T, Wünsch B, Goebels N, Meuth SG, Seebohm G, Melzer N.

Front Neurol. 2019 Mar 1;10:178. doi: 10.3389/fneur.2019.00178. eCollection 2019.

36.

Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients.

Kraemer M, Schwitalla JC, Diesner F, Aktas O, Hartung HP, Berlit P.

J Neurol. 2019 Jun;266(6):1421-1428. doi: 10.1007/s00415-019-09277-1. Epub 2019 Mar 13.

PMID:
30868219
37.

Remyelination in multiple sclerosis: from concept to clinical trials.

Kremer D, Göttle P, Flores-Rivera J, Hartung HP, Küry P.

Curr Opin Neurol. 2019 Jun;32(3):378-384. doi: 10.1097/WCO.0000000000000692.

PMID:
30865009
38.

Misdiagnoses and delay of diagnoses in Moyamoya angiopathy-a large Caucasian case series.

Graf J, Schwitalla JC, Albrecht P, Veltkamp R, Berlit P, Hartung HP, Aktas O, Kraemer M.

J Neurol. 2019 May;266(5):1153-1159. doi: 10.1007/s00415-019-09245-9. Epub 2019 Feb 25.

PMID:
30805794
39.

Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects.

Dietrich M, Aktas O, Hartung HP, Albrecht P.

Curr Opin Neurol. 2019 Jun;32(3):346-357. doi: 10.1097/WCO.0000000000000675.

PMID:
30694926
40.

Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats.

Dietrich M, Hecker C, Hilla A, Cruz-Herranz A, Hartung HP, Fischer D, Green A, Albrecht P.

J Vis Exp. 2019 Jan 10;(143). doi: 10.3791/58571.

PMID:
30688311
41.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group.

J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15.

42.

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.

Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN; PATH study group.

J Peripher Nerv Syst. 2019 Mar;24(1):72-79. doi: 10.1111/jns.12303. Epub 2019 Mar 1.

43.

Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study.

Hartung HP, Graf J, Kremer D.

J Neurol. 2019 Jan 4. doi: 10.1007/s00415-018-09169-w. [Epub ahead of print] Review.

PMID:
30610426
44.

Managing Risks with Immune Therapies in Multiple Sclerosis.

Förster M, Küry P, Aktas O, Warnke C, Havla J, Hohlfeld R, Mares J, Hartung HP, Kremer D.

Drug Saf. 2019 May;42(5):633-647. doi: 10.1007/s40264-018-0782-8. Review.

PMID:
30607830
45.

Monoclonal Antibodies for Multiple Sclerosis: An Update.

Graf J, Aktas O, Rejdak K, Hartung HP.

BioDrugs. 2019 Feb;33(1):61-78. doi: 10.1007/s40259-018-0327-9. Review.

PMID:
30604390
46.

Secretome analysis of nerve repair mediating Schwann cells reveals Smad-dependent trophism.

Schira J, Heinen A, Poschmann G, Ziegler B, Hartung HP, Stühler K, Küry P.

FASEB J. 2019 Apr;33(4):4703-4715. doi: 10.1096/fj.201801799R. Epub 2018 Dec 28.

PMID:
30592632
47.

High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.

Albrecht P, Jansen A, Lee JI, Moll M, Ringelstein M, Rosenthal D, Bigalke H, Aktas O, Hartung HP, Hefter H.

Neurology. 2019 Jan 1;92(1):e48-e54. doi: 10.1212/WNL.0000000000006688. Epub 2018 Nov 21.

PMID:
30464031
48.

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium.

J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.

PMID:
30447419
49.

Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination.

Göttle P, Förster M, Gruchot J, Kremer D, Hartung HP, Perron H, Küry P.

Glia. 2019 Jan;67(1):160-170. doi: 10.1002/glia.23535. Epub 2018 Nov 14.

PMID:
30430656
50.

Racial differences in neuromyelitis optica spectrum disorder.

Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz-Ching JL, Siritho S, Prayoonwiwat N, Shin HJ, Hyun JW, Han M, Leite MI, Palace J, Kim HJ.

Neurology. 2018 Nov 27;91(22):e2089-e2099. doi: 10.1212/WNL.0000000000006574. Epub 2018 Oct 26.

Supplemental Content

Loading ...
Support Center